Teva Pharma Repays Debt, Goodwill Impairment Nears $30B
Ticker: TEVJF · Form: 10-Q · Filed: May 7, 2025 · CIK: 818686
| Field | Detail |
|---|---|
| Company | Teva Pharmaceutical Industries Ltd (TEVJF) |
| Form Type | 10-Q |
| Filed Date | May 7, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: debt-repayment, goodwill-impairment, financial-reporting, sustainability-bonds
TL;DR
Teva paid down debt in early 2025, but goodwill impairment is still massive at $29.58B.
AI Summary
Teva Pharmaceutical Industries Ltd. filed a 10-Q for the period ending March 31, 2025. In January 2025, the company repaid $426 million and $427 million of its 6% and 7.13% senior notes, respectively. In March 2025, Teva repaid an additional $515 million of its 4.50% senior notes. As of March 31, 2025, cumulative goodwill impairment stood at approximately $29.58 billion.
Why It Matters
Teva's debt repayment demonstrates financial management, while the significant goodwill impairment suggests past acquisitions may not have performed as expected.
Risk Assessment
Risk Level: medium — The substantial goodwill impairment of $29.58 billion indicates potential overvaluation of past acquisitions, posing a financial risk.
Key Numbers
- $29.58B — Goodwill Impairment (As of March 31, 2025, indicating potential overvaluation of past acquisitions.)
- $426M — Senior Notes Repaid (In January 2025, part of debt management.)
- $427M — Senior Notes Repaid (In January 2025, part of debt management.)
- $515M — Senior Notes Repaid (In March 2025, part of debt management.)
Key Players & Entities
- TEVA PHARMACEUTICAL INDUSTRIES LTD (company) — Filer
- $29.58 billion (dollar_amount) — Cumulative goodwill impairment as of March 31, 2025
- $426 million (dollar_amount) — Repayment of 6% senior notes due 2025 in January 2025
- $427 million (dollar_amount) — Repayment of 7.13% senior notes due 2025 in January 2025
- $515 million (dollar_amount) — Repayment of 4.50% senior notes due 2025 in March 2025
- May 9, 2026 (date) — Earliest redemption date for sustainability-linked bonds premium payment
FAQ
What is the total amount of senior notes repaid by Teva in the first quarter of 2025?
Teva repaid a total of $1.368 billion in senior notes in the first quarter of 2025, consisting of $426 million in January, $427 million in January, and $515 million in March.
What is the current cumulative goodwill impairment for Teva Pharmaceutical Industries Ltd. as of March 31, 2025?
The cumulative goodwill impairment as of March 31, 2025, was approximately $29.58 billion.
What is the potential premium payment related to sustainability performance targets for Teva's bonds?
If Teva fails to achieve certain sustainability performance targets, a one-time premium payment of 0.15%-0.45% of the principal amount will be paid at maturity or upon earlier redemption on or after May 9, 2026.
What is the fair value estimation basis for contingent consideration?
Contingent consideration liabilities are recorded at fair value, estimated based on quoted market prices.
What is Teva's SIC code?
Teva's Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 7, 2025 regarding TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVJF).